Preserving the Integrity of Future Treatment:
ARV Regimens, Subsequent Choices,
and the Cost of Resistance

Earn CME/CE credits in one of two ways:

Click the Webinar link below to watch a panel of HIV experts discuss and interpret the findings of recent clinical trials, or click the Resource Compendium link below to view an online monograph and a downloadable PowerPoint slide set that build on the Webinar. Both the Resource Compendium and the Webinar focus on the following topics.

•
Resistance testing both before treatment initiation and after virologic failure
•
Initial ARV regimens in terms of the evolution of resistance among patients with virologic failure
•
Recent research findings related to the selection of viable first-line regimens for HIV-infected patients
•
The advantages and disadvantages of NNRTI-based and PI-based initial therapy
•
Minimizing the risk of maintaining nonsuppressive “holding” regimens
•
The evolution of resistance during early ARV treatment
 

The Resource Compendium will provide participants with:

• the opportunity to earn 2.0 hours of CME/CE credit for physicians,
   nurses, and pharmacists at a time convenient for them

• an online monograph and a downloadable slide set that may be repurposed for
   their own educational presentations

The on-demand Webinar will provide participants with:

• the opportunity to earn 1.0 hour of CME/CE credit for physicians, nurses,
   and pharmacists at a time convenient for them

• the opportunity to examine patient case studies, determining the
   challenges that HIV-treating professionals encounter daily


Supported by an educational grant from
Tibotec Therapeutics

CME/CE activity sponsored by AdvancMed